Centro de Investigación Clínica Chapultepec S. A. de C. V. - Morelia

Centro de Investigación Clínica Chapultepec S. A. de C. V. - Morelia
Gral. Manuel de La Pena y Pena 455, Chapultepec Nte., 58260 Morelia, Mich., Mexico
Select an option

Our team

Medical staff
Yurely Barrera
Monica Velazquez-Uncal
Octavio Aburto Valencia
Jose Manuel Loperena Herrera
Luis David Abraira Munoz
Diana Leal Corona
Daniela Jimenez
Daniela Pulido
Nadia Mondragón Gonzáles

Open studies

Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma - GOLSEEK-1 - CelgeneSee more
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma - EPCORE DLBCL-4 - AbbVieSee more
Pulmonary fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis - ALOFT-IPF - Bristol-Myers SquibbSee more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Lupus
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus - OPUS-1 - Idorsia Pharmaceuticals Ltd.See more
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy